Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2012

01-01-2012 | Preclinical study

Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients

Authors: Nabila Chaher, Hugo Arias-Pulido, Nadija Terki, Clifford Qualls, Kamel Bouzid, Claire Verschraegen, Anne Marie Wallace, Melanie Royce

Published in: Breast Cancer Research and Treatment | Issue 2/2012

Login to get access

Abstract

Inflammatory breast cancer (IBC) shows a high incidence in Tunisia and Egypt but epidemiological and molecular characteristics have not been described in Algeria. We compared 117 IBC and 59 non-IBC locally advanced breast cancers (LABC), for estrogen and progesterone receptors, HER2, and EGFR protein expression by immunohistochemistry, and HER2 gene amplification by chromogenic in situ hybridization. Demographic, clinico-pathological, and molecular variables were compared with chi-square and Fisher’s exact tests to test for significance (P < 0.05, two-tailed). Overall survival (OS) and disease-free survival (DFS) were plotted using Kaplan–Meier curves and compared using the log-rank test. Tumor emboli were detected in 77% of IBC. Palpable masses were found in all LABC but only in 32% of IBC (P < 0.001). Recurrences were higher in LABC than in IBC (48 vs. 35%; P = 0.14) but OS was worse in IBC (68 vs. 71%; P = 0.06). There were no significant differences between IBC and LABC by demographics or by clinico-pathological parameters. The majority of IBC and LABC tumors were luminal A (62 and 64%), followed by basal (~18%, each), triple negative (~18%, each), and HER2+ (~10%, each) subtypes. In multivariate analyses, grade was associated with worse OS (P = 0.04), and DFS (P < 0.001) in IBC; chemo- and radio-therapy were associated with improved OS and DFS, respectively (P < 0.05 for each) in LABC. In conclusion, IBC in Algeria shows similar characteristics to IBC described for Egypt and Tunisia with subtle molecular differences. Current therapeutic treatments were not very effective in this population and new approaches are much needed.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S et al (2010) International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. doi:10.1093/annonc/mdq345 Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S et al (2010) International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. doi:10.​1093/​annonc/​mdq345
2.
go back to reference Molckovsky A, Fitzgerald B, Freedman O, Heisey R, Clemons M (2009) Approach to inflammatory breast cancer. Can Fam Physician 55:25–31PubMed Molckovsky A, Fitzgerald B, Freedman O, Heisey R, Clemons M (2009) Approach to inflammatory breast cancer. Can Fam Physician 55:25–31PubMed
3.
go back to reference Singletary SE, Cristofanilli M (2008) Defining the clinical diagnosis of inflammatory breast cancer. Semin Oncol 35:7–10PubMedCrossRef Singletary SE, Cristofanilli M (2008) Defining the clinical diagnosis of inflammatory breast cancer. Semin Oncol 35:7–10PubMedCrossRef
4.
go back to reference Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97:966–975PubMedCrossRef Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97:966–975PubMedCrossRef
5.
go back to reference Boussen H, Bouzaiene H, Hassouna JB, Dhiab T, Khomsi F, Benna F, Gamoudi A, Mourali N, Hechiche M, Rahal K et al (2010) Inflammatory breast cancer in Tunisia. Cancer 116:2730–2735PubMedCrossRef Boussen H, Bouzaiene H, Hassouna JB, Dhiab T, Khomsi F, Benna F, Gamoudi A, Mourali N, Hechiche M, Rahal K et al (2010) Inflammatory breast cancer in Tunisia. Cancer 116:2730–2735PubMedCrossRef
6.
go back to reference Soliman A, Banerjee M, Lo A, Ismail K, Hablas A, Seifeldin I, Ramadan M, Omar H, Fokuda A, Harford J et al (2009) High proportion of inflammatory breast cancer in the Population-based Cancer Registry of Gharbiah, Egypt. Breast J 15:432–434PubMedCrossRef Soliman A, Banerjee M, Lo A, Ismail K, Hablas A, Seifeldin I, Ramadan M, Omar H, Fokuda A, Harford J et al (2009) High proportion of inflammatory breast cancer in the Population-based Cancer Registry of Gharbiah, Egypt. Breast J 15:432–434PubMedCrossRef
7.
go back to reference Mokhtar N, Elati J, Chabir R, Bour A, Elkari K, Schlossman NP, Caballero B, Aguenaou H (2001) Diet culture and obesity in Northern Africa. J Nutr 131:887S–892SPubMed Mokhtar N, Elati J, Chabir R, Bour A, Elkari K, Schlossman NP, Caballero B, Aguenaou H (2001) Diet culture and obesity in Northern Africa. J Nutr 131:887S–892SPubMed
8.
go back to reference Labidi SI, Mrad K, Mezlini A, Ouarda MA, Combes JD, Abdallah MB, Romdhane KB, Viens P, Ayed FB (2008) Inflammatory breast cancer in Tunisia in the era of multimodality therapy. Ann Oncol 19:473–480PubMedCrossRef Labidi SI, Mrad K, Mezlini A, Ouarda MA, Combes JD, Abdallah MB, Romdhane KB, Viens P, Ayed FB (2008) Inflammatory breast cancer in Tunisia in the era of multimodality therapy. Ann Oncol 19:473–480PubMedCrossRef
9.
go back to reference Dey S, Soliman A, Merajver S (2009) Xenoestrogens may be the cause of high and increasing rates of hormone receptor positive breast cancer in the world. Med Hypotheses 72:652–656PubMedCrossRef Dey S, Soliman A, Merajver S (2009) Xenoestrogens may be the cause of high and increasing rates of hormone receptor positive breast cancer in the world. Med Hypotheses 72:652–656PubMedCrossRef
10.
go back to reference Lo AC, Kleer CG, Banerjee M, Omar S, Khaled H, Eissa S, Hablas A, Douglas JA, Alford SH, Merajver SD et al (2008) Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients. Breast Cancer Res Treat 112:141–147PubMedCrossRef Lo AC, Kleer CG, Banerjee M, Omar S, Khaled H, Eissa S, Hablas A, Douglas JA, Alford SH, Merajver SD et al (2008) Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients. Breast Cancer Res Treat 112:141–147PubMedCrossRef
11.
go back to reference Duke T, Jahed N, Veneroso C, Da Roza R, Johnson O, Hoffman D, Barsky S, Levine P (2010) A cluster of inflammatory breast cancer (IBC) in an office setting: additional evidence of the importance of environmental factors in IBC etiology. Oncol Rep 24:1277–1284PubMed Duke T, Jahed N, Veneroso C, Da Roza R, Johnson O, Hoffman D, Barsky S, Levine P (2010) A cluster of inflammatory breast cancer (IBC) in an office setting: additional evidence of the importance of environmental factors in IBC etiology. Oncol Rep 24:1277–1284PubMed
12.
go back to reference Levine PH, Young HA, Mark L, Rojowsky H, Holland JF, Pogo BG (2009) Increased detection of breast cancer virus sequences in inflammatory breast cancer. Adv Tumor Virol 1:3–7 Levine PH, Young HA, Mark L, Rojowsky H, Holland JF, Pogo BG (2009) Increased detection of breast cancer virus sequences in inflammatory breast cancer. Adv Tumor Virol 1:3–7
13.
go back to reference Pogo B, Holland J, Levine P (2010) Human mammary tumor virus in inflammatory breast cancer. Cancer 116:2741–2744PubMedCrossRef Pogo B, Holland J, Levine P (2010) Human mammary tumor virus in inflammatory breast cancer. Cancer 116:2741–2744PubMedCrossRef
14.
go back to reference Charafe-Jauffret E, Mrad K, Intidhar Labidi S, Ben Hamida A, Ben Romdhane K, Ben Abdallah M, Ginestier C, Esterni B, Birnbaum D, Ben Ayed F et al (2007) Inflammatory breast cancers in Tunisia and France show similar immunophenotypes. Breast 16:352–358PubMedCrossRef Charafe-Jauffret E, Mrad K, Intidhar Labidi S, Ben Hamida A, Ben Romdhane K, Ben Abdallah M, Ginestier C, Esterni B, Birnbaum D, Ben Ayed F et al (2007) Inflammatory breast cancers in Tunisia and France show similar immunophenotypes. Breast 16:352–358PubMedCrossRef
15.
go back to reference Charafe-Jauffret E, Tarpin C, Bardou V, Bertucci F, Ginestier C, Braud A, Puig B, Geneix J, Hassoun J, Birnbaum D et al (2004) Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’. J Pathol 202:265–273PubMedCrossRef Charafe-Jauffret E, Tarpin C, Bardou V, Bertucci F, Ginestier C, Braud A, Puig B, Geneix J, Hassoun J, Birnbaum D et al (2004) Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’. J Pathol 202:265–273PubMedCrossRef
16.
go back to reference Ben Hamida A, Labidi IS, Mrad K, Charafe-Jauffret E, Ben Arab S, Esterni B, Xerri L, Viens P, Bertucci F, Birnbaum D et al (2008) Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin. BMC Cancer 8:28PubMedCrossRef Ben Hamida A, Labidi IS, Mrad K, Charafe-Jauffret E, Ben Arab S, Esterni B, Xerri L, Viens P, Bertucci F, Birnbaum D et al (2008) Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin. BMC Cancer 8:28PubMedCrossRef
17.
go back to reference Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, Bechlian D, Conte N, Adelaide J, Toiron Y, Nguyen C et al (2002) Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol 161:1223–1233PubMedCrossRef Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, Bechlian D, Conte N, Adelaide J, Toiron Y, Nguyen C et al (2002) Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol 161:1223–1233PubMedCrossRef
18.
go back to reference Van den Eynden G, Van der Auwera I, Van Laere S, Colpaert C, van Dam P, Merajver S, Kleer C, Harris A, Van Marck E, Dirix L et al (2004) Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat 85:13–22PubMedCrossRef Van den Eynden G, Van der Auwera I, Van Laere S, Colpaert C, van Dam P, Merajver S, Kleer C, Harris A, Van Marck E, Dirix L et al (2004) Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat 85:13–22PubMedCrossRef
19.
go back to reference Mourali N, Muenz L, Tabbane F, Belhassen S, Bahi J, Levine P (1980) Epidemiologic features of rapidly progressing breast cancer in Tunisia. Cancer 46:2741–2746PubMedCrossRef Mourali N, Muenz L, Tabbane F, Belhassen S, Bahi J, Levine P (1980) Epidemiologic features of rapidly progressing breast cancer in Tunisia. Cancer 46:2741–2746PubMedCrossRef
20.
go back to reference NCI/NHLBI OEITFM Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Bethesda, MD: NHLBI 1998 NCI/NHLBI OEITFM Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Bethesda, MD: NHLBI 1998
21.
go back to reference Arias-Pulido H, Smith H, Joste N, Bocklage T, Qualls C, Chavez A, Prossnitz E, Verschraegen C (2009) Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol 114:480–485PubMedCrossRef Arias-Pulido H, Smith H, Joste N, Bocklage T, Qualls C, Chavez A, Prossnitz E, Verschraegen C (2009) Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol 114:480–485PubMedCrossRef
22.
23.
go back to reference Lê MG, Arriagada R, Bahi J, Pfeiffer F, Cammoun M, Tabbane F, Rubino C (2006) Are risk factors for breast cancer similar in women with inflammatory breast cancer and in those with non-inflammatory breast cancer? The Breast 15:355–362PubMedCrossRef Lê MG, Arriagada R, Bahi J, Pfeiffer F, Cammoun M, Tabbane F, Rubino C (2006) Are risk factors for breast cancer similar in women with inflammatory breast cancer and in those with non-inflammatory breast cancer? The Breast 15:355–362PubMedCrossRef
24.
go back to reference Lo A, Georgopoulos A, Kleer C, Banerjee M, Omar S, Khaled H, Eissa S, Hablas A, Omar H, Douglas J et al (2009) Analysis of RhoC expression and lymphovascular emboli in inflammatory vs. non-inflammatory breast cancers in Egyptian patients. Breast 18:55–59PubMedCrossRef Lo A, Georgopoulos A, Kleer C, Banerjee M, Omar S, Khaled H, Eissa S, Hablas A, Omar H, Douglas J et al (2009) Analysis of RhoC expression and lymphovascular emboli in inflammatory vs. non-inflammatory breast cancers in Egyptian patients. Breast 18:55–59PubMedCrossRef
25.
go back to reference Chang S, Alderfer J, Asmar L, Buzdar A (2000) Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis. Breast Cancer Res Treat 64:157–163PubMedCrossRef Chang S, Alderfer J, Asmar L, Buzdar A (2000) Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis. Breast Cancer Res Treat 64:157–163PubMedCrossRef
26.
go back to reference Aziz SA, Pervez S, Khan S, Kayani N, Azam SI, Rahbar MH (2001) Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience. Breast J 7:398–404PubMedCrossRef Aziz SA, Pervez S, Khan S, Kayani N, Azam SI, Rahbar MH (2001) Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience. Breast J 7:398–404PubMedCrossRef
27.
go back to reference Chang S, Buzdar AU, Hursting SD (1998) Inflammatory breast cancer and body mass index. J Clin Oncol 16:3731–3735PubMed Chang S, Buzdar AU, Hursting SD (1998) Inflammatory breast cancer and body mass index. J Clin Oncol 16:3731–3735PubMed
28.
go back to reference Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player AN et al (2010) Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 60:351–375PubMedCrossRef Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player AN et al (2010) Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 60:351–375PubMedCrossRef
29.
go back to reference Dey S, Soliman A, Hablas A, Seifeldein I, Ismail K, Ramadan M, El-Hamzawy H, Wilson M, Banerjee M, Boffetta P et al (2010) Urban–rural differences in breast cancer incidence in Egypt (1999–2006). Breast 16:417–423CrossRef Dey S, Soliman A, Hablas A, Seifeldein I, Ismail K, Ramadan M, El-Hamzawy H, Wilson M, Banerjee M, Boffetta P et al (2010) Urban–rural differences in breast cancer incidence in Egypt (1999–2006). Breast 16:417–423CrossRef
30.
go back to reference Gruber G, Ciriolo M, Altermatt H, Aebi S, Berclaz G, Greiner R (2004) Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer. Int J Cancer 109:144–148PubMedCrossRef Gruber G, Ciriolo M, Altermatt H, Aebi S, Berclaz G, Greiner R (2004) Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer. Int J Cancer 109:144–148PubMedCrossRef
31.
go back to reference Le M, Arriagada R, Contesso G, Cammoun M, Pfeiffer F, Tabbane F, Bahi J, Dilaj M, Spielmann M, Travagli J et al (2005) Dermal lymphatic emboli in inflammatory and noninflammatory breast cancer: a French-Tunisian joint study in 337 patients. Clin Breast Cancer 6:439–445PubMedCrossRef Le M, Arriagada R, Contesso G, Cammoun M, Pfeiffer F, Tabbane F, Bahi J, Dilaj M, Spielmann M, Travagli J et al (2005) Dermal lymphatic emboli in inflammatory and noninflammatory breast cancer: a French-Tunisian joint study in 337 patients. Clin Breast Cancer 6:439–445PubMedCrossRef
32.
go back to reference Dawood S, Ueno N, Cristofanilli M (2008) The medical treatment of inflammatory breast cancer. Semin Oncol 35:64–71PubMedCrossRef Dawood S, Ueno N, Cristofanilli M (2008) The medical treatment of inflammatory breast cancer. Semin Oncol 35:64–71PubMedCrossRef
33.
go back to reference Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377–384PubMedCrossRef Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377–384PubMedCrossRef
34.
go back to reference Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML et al (2008) Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 26:1066–1072PubMedCrossRef Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML et al (2008) Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 26:1066–1072PubMedCrossRef
35.
go back to reference Kaufman B, Trudeau M, Awada A, Blackwell K, Bachelot T, Salazar V, DeSilvio M, Westlund R, Zaks T, Spector N et al (2009) Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 10:581–588PubMedCrossRef Kaufman B, Trudeau M, Awada A, Blackwell K, Bachelot T, Salazar V, DeSilvio M, Westlund R, Zaks T, Spector N et al (2009) Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 10:581–588PubMedCrossRef
36.
go back to reference Boussen H, Cristofanilli M, Zaks T, DeSilvio M, Salazar V, Spector N (2010) Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol 28:3248–3255PubMedCrossRef Boussen H, Cristofanilli M, Zaks T, DeSilvio M, Salazar V, Spector N (2010) Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol 28:3248–3255PubMedCrossRef
Metadata
Title
Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients
Authors
Nabila Chaher
Hugo Arias-Pulido
Nadija Terki
Clifford Qualls
Kamel Bouzid
Claire Verschraegen
Anne Marie Wallace
Melanie Royce
Publication date
01-01-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1422-5

Other articles of this Issue 2/2012

Breast Cancer Research and Treatment 2/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine